ORIGINAL RESEARCH article

Front. Oncol.

Sec. Cancer Molecular Targets and Therapeutics

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1591430

This article is part of the Research TopicNovel Molecular Targets in Cancer TherapyView all 28 articles

Uncovering Key Regulatory Pathways and Prognostic Biomarkers in the Tumor Microenvironment of High-Grade Serous Ovarian Cancer Through Single-Cell RNA Sequencing and Experimental Validation

Provisionally accepted
Yue  LiYue Li1Long  ZhaoLong Zhao2YING  TIANYING TIAN2Qianqian  ZhouQianqian Zhou3Xia  LiuXia Liu1Shucai  YangShucai Yang4Jinfeng  XuJinfeng Xu2Chang  ZouChang Zou5Jinling  ZhangJinling Zhang2*Hui  LuoHui Luo2
  • 1Shenzhen Second People's Hospital, Shenzhen, Guangdong Province, China
  • 2shenzhen people'hospital, Shenzhen, China
  • 3Southern University of Science and Technology, Shenzhen, Guangdong Province, China
  • 4Pingshan General Hospital, Shenzhen, China
  • 5Department of Clinical Medical Research Center, The Second Clinical Medical College, Jinan University (Shenzhen People’s Hospital), Shenzhen, China

The final, formatted version of the article will be published soon.

Background: High-grade serous ovarian cancer (HGSOC) is a leading cause of cancerrelated deaths among women globally. This study aims to identify novel regulatory targets and signaling pathways that modulate the tumor microenvironment (TME) in HGSOC, focusing on the pleiotrophin (PTN) signaling pathway and syndecan 4 (SDC4) expression as potential biomarkers for prognosis. Methods: Bioinformatics analysis was conducted on single-cell RNA sequencing (scRNA-seq) data (GSE146026) of HGSOC to investigate the TME. The data were subjected to unsupervised clustering to classify cell types within the TME, revealing eight distinct clusters representing various cell types. Cell-cell interactions were analyzed using the CellChat tool. Additionally, TCGA datasets were used to validate the expression of SDC4 and its association with clinical outcomes. The functional enrichment of differentially expressed genes (DEGs) between high and low SDC4 expression groups was performed to uncover associated pathways. Experimental validation was carried out using quantitative real-time PCR (qRT-PCR) and Western blotting on ovarian cancer cell lines (OVCAR3 and SKOV3).The unsupervised clustering analysis revealed eight major cell types: macrophages, fibroblasts, ovarian cancer cells, B cells, T cells, dendritic cells, and erythrocytes. CellChat analysis highlighted significant interactions between these cell types, suggesting a complex TME. Further exploration identified PTN signaling as a key regulator within the HGSOC TME. Validation using TCGA datasets revealed upregulation of SDC4 in ovarian cancer tissues, with high SDC4 expression correlating with shorter overall survival. DEGs between high and low SDC4 expression groups were linked to the PI3K-Akt and MAPK signaling pathways, cell junction organization, and focal adhesion. qRT-PCR validation confirmed a significant upregulation of SDC4 in OVCAR3 and SKOV3 ovarian cancer cell lines, with expression levels 3.8-to 4.2fold higher than control cells (p<0.01), supporting the computational predictions.This study highlights the PTN signaling pathway as a potential therapeutic target in HGSOC and identifies SDC4 as a prognostic biomarker for poor patient outcomes. Our findings offer new insights into the molecular mechanisms governing the TME of HGSOC, although further investigation is needed to fully elucidate the functional role of SDC4 in ovarian cancer progression.

Keywords: High-grade serous ovarian cancer (HGSOC), Tumor microenvironment (TME), Pleiotrophin (PTN) signaling, Syndecan 4 (SDC4), single-cell RNA sequencing (scRNA-seq), experimental validation

Received: 11 Mar 2025; Accepted: 14 Apr 2025.

Copyright: © 2025 Li, Zhao, TIAN, Zhou, Liu, Yang, Xu, Zou, Zhang and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Jinling Zhang, shenzhen people'hospital, Shenzhen, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more